title: Atypical autoimmune adverse effects with checkpoint blockade therapies.
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.|Weill Cornell Medical College, New York, USA.
authors.forename: C F
authors.initials: CF
authors.lastname: Friedman
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.|Weill Cornell Medical College, New York, USA.
authors.forename: A
authors.initials: A
authors.lastname: Snyder
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D006801:Humans; D007154:Immune System Diseases / Q000139:chemically induced* / Q000276:immunology; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor